<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02656914</url>
  </required_header>
  <id_info>
    <org_study_id>EMS1115</org_study_id>
    <nct_id>NCT02656914</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Irlanda-2-Association on the Treatment of Common Cold</brief_title>
  <official_title>Phase III, National, Multicenter, Randomized, Double Blind Clinical Trial, to Evaluate the Efficacy and Safety of Irlanda-2-Association on the Treatment of Common Cold</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EMS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EMS</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the clinical efficacy of the drug associations in
      the treatment of common cold
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Double blind,randomized, multicenter; Maximal experiment duration: 7 days; 03 visits; Safety
      and efficacy evaluation
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2018</start_date>
  <completion_date type="Anticipated">May 2019</completion_date>
  <primary_completion_date type="Anticipated">February 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double blind study</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Determine efficacy of Irlanda-2-Association in the treatment of common cold symptoms.</measure>
    <time_frame>7 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety Will be Evaluated by the Adverse Events Occurrences</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">530</enrollment>
  <condition>Common Cold</condition>
  <arm_group>
    <arm_group_label>Irlanda-2-Association</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Take 10 mL every 12 hours (2x/day), oral route.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Take 10 mL every 12 hours (2x/day), oral route.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irlanda-2-Association</intervention_name>
    <description>Take 10 mL every 12 hours (2x/day), oral route.</description>
    <arm_group_label>Irlanda-2-Association</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Take 10 mL every 12 hours (2x/day), oral route.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant within 48 hours of the onset of common cold symptoms: headache, sneezing,
             sore throat, nasal obstruction, cough, coryza and body pain;

          -  Signed Consent of the patient.

        Exclusion Criteria:

          -  Patients with any clinically significant disease that in the investigator is opinion
             can´t participate in the study;

          -  Patients with any laboratory finding or image finding that in the investigator is
             opinion can´t participate in the clinical trial;

          -  Patients with history of hypersensitivity to any of the formula compounds;

          -  Participation in clinical trial in the year prior to this study;

          -  Patients with vaccine reaction;

          -  Patients who have uncontrolled asthma however, participants in use of pulmonary
             corticosteroids (alone or in combination with other products) will be allowed if they
             are in stable dose and diagnosed with controlled asthma;

          -  Patients with gastroesophageal reflux, gastric or duodenal ulcer or other serious
             disease of the gastrointestinal tract;

          -  Patients with diabetes mellitus type I and II;

          -  Pregnancy or risk of pregnancy and lactating patients;

          -  Patients who were in use of drugs that can interfere with flu symptoms evaluation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Monalisa F.B. Oliveira, M.D.</last_name>
    <phone>+551938879851</phone>
    <email>pesquisa.clinica@ems.com.br</email>
  </overall_contact>
  <location>
    <facility>
      <name>Allergisa</name>
      <address>
        <city>Campinas</city>
        <state>São Paulo</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 12, 2016</study_first_submitted>
  <study_first_submitted_qc>January 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2016</study_first_posted>
  <last_update_submitted>January 8, 2018</last_update_submitted>
  <last_update_submitted_qc>January 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Common Cold</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

